References

  1. Trétarre B, Remontet L, Ménégoz F, Mace-Lesec'h J, Grosclaude P, Buemi A et al. Ovarian cancer: incidence and mortality in france. J Gynecol Obstet Biol Reprod. 2005;34:154-61. PubMed | Google Scholar

  2. Argento M, Hoffman P, Gauchez AS. Le cancer de l'ovaire et les perspectives d'amélioration de la précocité du diagnostic. Immuno-analyse et biologie spécialisée. 2008;23:251-9. PubMed | Google Scholar

  3. Le Roux C, Sentilhes L, Catala L, Lefebvre-Lacoeuille C, Poilblanc M, Descamps P. Laparoscopy for surgical treatment for uterine and ovarian cancer in France: a national practice survey. J Gynecol Obstet Biol Reprod. 2011;40(3):231-6. PubMed | Google Scholar

  4. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009; 374:1371-82. PubMed | Google Scholar

  5. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: Cancer incidence, mortality and prevalence worldwide. Lyon, IARC Press. 2001. PubMed | Google Scholar

  6. Benoit L, Désir JP, Fraisse J, Arnould L, Cuisenier J. Evolution of therapeutic practices and survival of ovarian cancer in Bourgandi between 1982-1996: a registry-based study. Ann Chir. 2004; 129(8):415-21. PubMed | Google Scholar

  7. Chene G, Penault-Llorca F, Robin N, Cayre A, Provencher DM, Dauplat J. Early detection of ovarian cancer: tomorrow? A review. J Gynecol Obstet Biol Reprod. 2013; 42(1):5-11. PubMed | Google Scholar

  8. US. Preventive Services Task Force Screening for ovarian cancer: recommendation statement. Ann Fam Med. 2004; 2:260-2. PubMed | Google Scholar

  9. Sommelet D, Pinkerton R, Brunat-Mentigny M, Farsi F, Martel I, Philip T et al. Standards, options and recommendations (SOR) for clinical care of rhabdomyosarcoma (RMS) and other soft tissue sarcoma in children Federation of the French Cancer Centers French Society of Pediatric Oncology. Bull Cancer. 1998; 85(12):1015-42. PubMed | Google Scholar

  10. Coates RJ, Kolor K, Stewart SL, Richardson LC. Diagnostic markers for ovarian cancer screening: not ready for routine clinical use. Clin Cancer Res. 2008;14:7575-6. PubMed | Google Scholar

  11. Coussy F, Chéreau E, Daraï E, Dhombres F, Lotz JP, Rouzier R et al. Interest of CA 125 level in management of ovarian cancer. Gynecol Obstet Fertil. 2011; 39(5):296-301. PubMed | Google Scholar

  12. Furet E, Chéreau E, Lambaudie E, Bannier M, Houvenaeghel G. Feasibility, morbidity and survival of surgery combined with HIPEC in the management of recurrent ovarian cancer. Gynecol Obstet Fertil. 2013; 41(9):493-8. PubMed | Google Scholar

  13. Grove S, Quinn MA, Weidman P. Hoon Koh; factors influencing serum CA125 levels in normal women. Obstet Gynecol. 1992; 79:511-4. PubMed | Google Scholar

  14. Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih IeM, et al. Evaluation of DNA from the papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013; 5:167ra4. PubMed | Google Scholar

  15. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107(1):77-85. PubMed | Google Scholar

  16. Classe JM, Cerato E, Boursier C, Dauplat J, Pomel C, Villet R,et al. Retroperitoneal lymphadenectomy and survival of patients treated for an advanced ovarian cancer: the CARACO trial. J Gynecol Obstet Biol Reprod. 2011; 40(3):201-4. PubMed | Google Scholar

  17. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004; 351:2519-29. PubMed | Google Scholar

  18. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20(5):1248-59. PubMed | Google Scholar

  19. Jaffre I, Bordes V, Dejode M, Dravet F, Frenel JS, Berton-Rigaud D et al. The role of interval surgery in the treatment's strategy of advanced ovarian cancer. Bull cancer. 2011; 98 (1):37-42. PubMed | Google Scholar

  20. Ben Fatma L, Hochlef M, Gharbi O, Landolsi A, Limam S, Chabchoub I, et al. Epithelial advanced ovarian carcinoma in the central region of tunisia: therapeutic results and prognostic factors on 104 patients. Bull cancer. 2006; 93(12):1233-9. PubMed | Google Scholar

  21. Fanfani F, Ferrandina G, Corrado G, Fagotti A, Zakut HV, Mancuso S, et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology. 2003; 65(4):316-22. PubMed | Google Scholar

&